09.10 14:32 | dpa-AFX: Johnson & Johnson Buys Privately-held V-Wave; Sees In-process R&D Charge Of Around $600 Mln In Q4 |
09.10 14:03 | dpa-AFX: *JOHNSON & JOHNSON COMPLETES ACQUISITION OF PRIVATELY-HELD COMPANY V-WAVE |
04.10 16:55 | dpa-AFX: JNJ To Terminate Phase 2 Field Study Of Mosnodenvir For Prevention Of Dengue Virus |
04.10 16:22 | dpa-AFX: *JOHNSON & JOHNSON DISCONTINUES PHASE 2 STUDY OF MOSNODENVIR FOR DENGUE PREVENTION |
02.10 16:31 | dpa-AFX: JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer |
02.10 15:03 | dpa-AFX: *J&J : ERLEADA SHOWS SIGNIFICANT SURVIVAL BENEFITS OVER ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER |
30.09 15:04 | dpa-AFX: Johnson & Johnson Expands Roll-out Of TECNIS Odyssey IOL |
30.09 14:11 | dpa-AFX: *J&J LAUNCHES TECNIS ODYSSEY LENS FOR PRECISE VISION AT EVERY DISTANCE AND LIGHTING |
28.09 09:02 | dpa-AFX: J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD Negativity In Newly Diagnosed Multiple Myeloma |
28.09 08:14 | dpa-AFX: J&J : Phase 3 Trial Results Show CARVYKTI Extends Overall Survival In Relapsed Multiple Myeloma |
27.09 22:26 | dpa-AFX: Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma |
27.09 14:49 | dpa-AFX: Johnson & Johnson Reports New Data From Phase 1b TRIMM-2 Study |
27.09 14:30 | dpa-AFX: J&J Reports Data From Investigational Phase 1b RedirecTT-1 Study |
27.09 14:10 | dpa-AFX: *J&J : TALVEY AND TECVAYLI SHOW HIGH RESPONSE RATES IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA |
27.09 14:07 | dpa-AFX: *JOHNSON & JOHNSON ANNOUNCES PHASE 1B TRIMM-2 RESULTS EVALUATING TALVEY WITH DARZALEX FASPRO |
27.09 09:34 | EU-Zulassung für Stelara-Biosimilar von Formycon und Fresenius Kabi |
21.09 07:21 | dpa-AFX: J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims |
20.09 14:04 | dpa-AFX: Janssen-Cilag Reports CHMP Recommendation For Daratumumab |
20.09 13:43 | dpa-AFX: *J&J : DARZALEX QUADRUPLET REGIMEN GETS POSITIVE CHMP OPINION FOR NEWLY DIAGNOSED MYELOMA PATIENTS |
20.09 02:47 | dpa-AFX: FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy |
|